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Abstract We evaluated the radiation outcome and prog-
nostic factors in a population-based study of early
(T1N0M0) glottic carcinoma. Survival parameters and
prognostic factors were evaluated by uni- and multivariate
analysis in 316 consecutive irradiated patients with T1 glot-
tic carcinoma in the Comprehensive Cancer Center West
region of the western Netherlands. Median follow-up was
70 months (range 1–190 months). Five and ten-year local
control was 86 and 84%. Disease speciWc survival was 97%
at 5 and 10 years. In multivariate analysis, pre-existent
laryngeal hypertrophic laryngitis was the only predictive
factor for local control (relative risk = 3.0, P = 0.02).
Comorbidity was prognostic for overall survival. No factor
was predictive for disease speciWc survival. Pre-existent
laryngeal hypertrophic laryngitis is a new risk factor associ-
ated with reduced local control in T1 glottic carcinoma
treated with radiotherapy.
Keywords Population-based · Glottic · Carcinoma · T1 · 
Radiotherapy · Local control · Prognostic factors
Introduction
Laryngeal carcinoma is the most frequently diagnosed
malignant head and neck tumor in Western Europe and the
United States. Based on the records of the Netherlands Can-
cer Registry, 64% of these are glottic carcinomas of which
more than half (56%) are diagnosed as “early glottic carcino-
mas” (T1) [1]. Radiotherapy provides successful treatment
results with local control rates between 80 and 95% and dis-
ease-speciWc survival from 92 to 97% in large studies [2–5].
Rendering high-cure rates and what is generally accepted as
good voice quality, irradiation as yet remains the cornerstone
of treatment in many clinics with endoscopic laser surgery
reserved only for small, selected mid-cord lesions [6]. How-
ever, despite high rates of local control, small number of
tumors will recur. In many of these patients, laryngectomy
will be unavoidable with severe impact on quality of life. To
identify patient, tumor or treatment characteristics that are
associated with failure of radiation therapy would therefore
be of advantage, as these patients may need adjusted treat-
ment or more thorough follow-up.
Many retrospective studies on prognostic factors have
been undertaken and the literature is contradictory and often
confusing. As of yet the evidence from randomized, prospec-
tive studies is minimal [7]. Table 1 shows treatment outcome
(local control) and Wndings for prognostic factors in large
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736 Eur Arch Otorhinolaryngol (2009) 266:735–744studies (more 100 patients) on T1 glottic carcinoma, treated
with radiotherapy since 1990 [3, 5–21]. It is clear that in spite
of reasonable steady rates of local control there are consider-
able discrepancies between Wndings on prognostic factors.
What is also interesting is that most studies fail to show a sig-
niWcant impact on local control of the time-dose related fac-
tors, total dose, fraction dose and overall treatment time,
which are generally considered important determinants of
treatment outcome. The reasons for the contradictory results
are several. Studies diVer considerably in size and most stud-
ies are institution based, which may introduce referral bias.
The choice of prognostic factors is diverse, cut-oV points for
subgroups within a speciWc prognostic factor are wide rang-
ing and some studies do not perform stratiWcation or multi-
variate analysis. Also, recurrences are relatively uncommon,
which means there are few events within the subgroups of a
speciWc prognostic factor. Several studies include T2 lesions
in their analysis. These studies were purposely excluded
from Table 1 as there is much evidence to suggest that T2
lesions have signiWcantly worse treatment outcome than T1
lesions [2, 12, 22, 23]. We therefore believe that they should
be treated as a separate entity. The conclusion must be that,
after many years and many studies we are still not sure of the
optimum time-dose related treatment schedule for T1 glottic
carcinoma and of further factors that possibly predict radiore-
sistance in these tumors.
The purpose of the present study was to evaluate treat-
ment outcome and prognostic factors in T1 glottic carci-
noma treated with radiotherapy within the Comprehensive
Cancer Center West (CCCW) region of the Netherlands. By
focusing on T1 tumors and using a population-based study
design, we aimed to increase the validity of our Wndings on
tumor and treatment related prognostic factors. The choice
of prognostic factors was based on results of large studies
on irradiated early glottic carcinoma [3, 5–21].
Patients and methods
The study was conducted in the region of the Comprehen-
sive Cancer Center West (CCCW), with 1.6 million inhabit-
ants. This region harbors one of nine cancer registries in the
Netherlands where all cancers are registered. It covers a het-
erogeneous district in the west of the Netherlands with both
urban and rural areas. Four irradiation centers serve this dis-
trict. All patients diagnosed with primary early glottic carci-
noma, diagnosed in this region between 1982 and 1993,
were included in this study. The cut-oV date was chosen
based on the fact that from 1994 onwards laser surgery was
being used in selected cases, Wrst as an experimental therapy
and later as a routine treatment procedure. Five patients
were eventually irradiated outside the region, but were fully
included in the study. Treatment consisted of radiotherapy
in 282 patients, radiotherapy and microsurgery in 34
patients and microsurgery alone in 1 patient. Dual treatment
involved surgical excision prior to radiotherapy. Two
patients were not treated at all due to advanced lung disease
at the time of diagnosis. Thus, a total of 316 patients were
treated with radiotherapy and qualiWed for analysis.
Data were collected by retrospective review of patient
charts as well as of hospital and regional cancer registries.
The regional cancer registry was actively updated by trained
health workers for this project. All patients had been staged
by direct laryngoscopy and biopsy. Characteristics of patient
(age, sex, comorbidity, pre-existent laryngeal hypertrophic
laryngitis, smoking habit, smoking during irradiation and
symptom duration), tumor (substage, anterior commissure
involvement, diVerentiation and size) and radiotherapy
(beam energy, total dose, dose per fraction, overall treatment
time, treatment regimen, Weld size, treatment delay, addi-
tional mode and treatment era) were recorded.
Patient characteristics
Patient characteristics are summarized in Table 2. Age
ranged from 37 to 91 (median 66 years) and was divided
into four categories. Pre-existent laryngeal hypertrophic
laryngitis was deWned as non-malignant lesions (chronic
laryngitis, leukoplakia or hyperkeratosis) recorded clini-
cally or by pathological examination at some time prior to
diagnosis. Evidence for pre-existent laryngeal hypertrophic
laryngitis was found in 24 patients. To further characterize
this subgroup, pathology reports were traced in the hospital
and national database (Table 3). Comorbid disease was
scored as present or absent disregarding the number and
severity of the individual diseases. In the category smoking
habits, ex-smokers were deWned as patients who had
stopped at least 10 years prior to diagnosis. Symptom dura-
tion was deWned as time between Wrst symptoms and diag-
nosis in months and was divided into three groups.
Tumor characteristics
Tumor characteristics are summarized in Table 4. Tumor
stage was T1a or T1b. Seven tumors, localized only in the
anterior commissure were excluded from analysis of sub-
stage, as they were neither T1a nor T1b. The size of the
tumor was estimated by summating the number of aVected
thirds of the vocal cords and was divided into three groups.
Treatment characteristics
The treatment characteristics are summarized in Table 5.
Radiotherapy was delivered with 60Co or linear accelerator.
Treatment with a linear accelerator was 4-MV (n = 4), 5-MV
(n = 85), 6 MV (n = 59) or 8 MV (n = 4). There were four123
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738 Eur Arch Otorhinolaryngol (2009) 266:735–744diVerent treatment centers (a–d). Dosage was prescribed at
midplane, isodose level or according to ICRU 29. For the
purpose of this study, all doses were re-calculated accord-
ing to ICRU 29. Total dose ranged from 54 to 76 Gy
(median 60 Gy) and was divided into two groups, 60 Gy or
less and more than 60 Gy. Dose per fraction ranged from 2
to 2.8 Gy (median 2 Gy) and was divided into two groups,
2 Gy and more than 2 Gy. Because of the complex time-
dose relationship we compared not only separate treatment
variables but also whole treatment schedules. Due to varia-
tions in dosage prescription, however, there were too many
treatment schedules for individual, comparative analysis.
Therefore we divided schedules in two groups: group 1
consisting of the most frequent schedule of 30 £ 2 Gy
(including 1 patient with 27 £ 2 Gy) and group 2 consist-
ing of “additional treatment” either through a higher dose
than 2 Gy per fraction or a higher number of fractions than
30. Treatment duration was divided in two groups: 42 days
or shorter and longer than 42 days.
To exclude confounding inXuence of varying total doses
and fraction doses on the eVect of overall treatment time on
local control, overall treatment time was also tested sepa-
rately in the subgroup of patients that all received 60 Gy
(30 £ 2) total dose. The local control rates for a treatment
duration of 42 days or shorter were compared to that of a
duration of longer than 42 days by log-rank testing. Field
size ranged from 25 to 100 cm2 (median 36 cm2) and was
divided into two groups: smaller than 35 cm2 and 35 cm2 or
larger. Treatment delay from time of diagnosis to time of
radiotherapy ranged from 1 to 183 days (median of 21 days)
and was divided into two groups: smaller or equal to 25 days
and more than 25 days. Thirty-four patients received addi-
tional microsurgery prior to radiotherapy. Finally, the study
period was divided into three eras of 4 years each.
End points and statistical analysis
Data were analyzed using SPSS10. Follow-up was calcu-
lated in months from the Wrst day of radiotherapy to the
Table 2 Histology in patients with pre-existent laryngeal pathology
a As the pathological diagnosis is often a mix of histological entities
incidence per entity is not detailed separately
Histological diagnosis n Time before T1
No prior histological examination 13 –
Prior histological examinationa 
(hyperkeratosis, hyperplasia or 
light dysplasia corresponding to 
clinical leukoplakia and/
or chronic laryngitis)
11 Mean 16 months
Median 13 months
Range 6–36 months
Table 3 Patient characteristics and 5-year local control for T1 tumors
a Smoking: 12 missing values. Smoking during RT: 100 missing val-
ues. Symptom duration: 22 missing values. Irradiation center: Wve pa-
tients excluded due to treatment in other centers
n = 316 (%) Local 
control (%)
P value 
(log-rank)
Sex
Male 284 (90) 86 0.52
Female 32 (10) 90
Age
<50 years 32 (10) 84 0.77
50–59 years 65 (21) 88
60–69 years 104 (33) 89
¸70 years 115 (36) 83
Pre-existent hypertrophic laryngitis
Yes 24 (8) 77 0.07
No 292 (92) 87
Comorbidity
Yes 116 (37) 87 0.23
No 200 (63) 84
Smokinga
Non-smoker 70 (23) 89 0.27
Ex-smoker 36 (12) 94
Smoker 198 (65) 84
Smoking during RTa
Yes 51 (24) 81 0.12
No 165 (76) 89
Symptom durationa
1–3 months 108 (37) 86 0.91
4–6 months 95 (32) 84
7 or more months 91 (31) 86
Table 4 Tumor characteristics and 5-year control for T1 tumors
a Stage: 7 tumors localized solely in the anterior commissure are ex-
cluded. DiVerentiation: 82 missing values. Size: 4 missing values
n = 316 (%) Local 
control (%)
P value 
(log-rank)
Stagea
T1a 210 (68) 87 0.38
T1b 99 (32) 85
Anterior commissure
Yes 106 (34) 85 0.38
No 210 (66) 87
DiVerentiationa
Good 63 (27) 83 0.24
Moderate 154 (66) 88
Poor 17 (7) 100
Sizea
1/3 88 (28) 91 0.07
2/3 114 (37) 80
3/3–6/3 110 (35) 89123
Eur Arch Otorhinolaryngol (2009) 266:735–744 739date of the last follow-up or time of death. The recurrence
free interval for local control ran from the Wrst day of radio-
therapy to the date of the Wrst recurrence, time of death or
withdrawal from the study. Follow-up data of patients lost
to follow-up were included in analysis up to the point of
loss. Local recurrence was deWned as all recurrences
involving the initial tumor site. Treatment outcome was
evaluated by 5- and 10-year overall survival, disease spe-
ciWc survival and local control, using the Kaplan–Meier
method. Univariate analysis was carried out by means of
log-rank testing. All signiWcant factors along with those of
borderline signiWcance (deWned as P · 0.20) were then
entered into multivariate analysis using the Cox propor-
tional hazard model. The variable smoking during radio-
therapy, although qualifying for entry, was left out of
multivariate analysis as the large amount of missing values
in this category would considerably weaken the analysis.
Results
In 316 patients included the study, there was a male to
female ratio of 8:1 (284 males and 32 females). Age ranged
from 37 to 91 with a median of 66 years. Median follow up
was 70 months (range 1–190 months). The median follow-
up for patients still alive was 80 months with 80% of these
patients having at least 5 years of follow-up. In total, there
were 46 cases of recurrent disease of which 38 were local, 5
local with regional involvement, 1 regional and 2 distant. In
ten cases, the local recurrence consisted of residual disease
adjacent to treatment.
Local control
Five- and 10-year local control rates were 86 and 84%. The
results of the univariate analysis of the inXuence of patient,
tumor and treatment characteristics on local control are
shown in Tables 2, 4 and 5. No single factor showed true
signiWcance. However, pre-existent laryngeal hypertrophic
laryngitis (P = 0.07), tumor size (P = 0.07), total doses
(P = 0.09), treatment duration (P = 0.18), treatment delay
(P = 0.10), treatment era (P = 0.18) and regimen (P = 0.08)
were of borderline signiWcance, as deWned earlier, and were
therefore entered into multivariate analysis. Smoking dur-
ing radiotherapy was also of borderline signiWcance
(P = 0.12) but was left out of analysis as explained earlier.
To exclude confounding inXuence of varying total doses
and fraction doses on the eVect of overall treatment time on
local control, overall treatment time was also tested sepa-
rately (log-rank) in the subgroup of patients that all
received 60 Gy (30 £ 2) total dose. In this test, overall
treatment time did not aVect local control (P = 0.95) in this
group. In multivariate analysis, only pre-existent laryngeal
hypertrophic laryngitis was found to be of signiWcant inXu-
ence on recurrent disease. Patients with pre-existent laryn-
geal hypertrophic laryngitis had a higher rate of recurrence
(P = 0.02) with a relative risk of 3.0 (95% CI 1.2–7.2)
(Table 6).
Disease-speciWc survival
Twelve patients died as a result of their glottic tumor. Ten
of these patients had undergone total laryngectomy, one
Table 5 Treatment characteristics and 5-year local control for T1
tumors
a Unit and norm: three missing values. Overall treatment time and
treatment delay: one missing value. Schedule, total dose and fraction
dose: two missing values. Field area: ten missing values
n = 316 (%) Local 
control (%)
P value 
(log-rank)
Unita
Cobalt 161 (51) 87 0.50
Linear accelerator 152 (49) 85
Irradiation centera
a 133 (43) 86 0.65
b 25 (8) 84
c 49 (16) 87
d 104 (33) 87
Schedulea
1 (30 £ 2 Gy) 157 (50) 84 0.08
2 (other) 157 (50) 89
Overall treatment timea
<42 days 89 (28) 83 0.18
¸42 days 226 (72) 88
Total dosea
·60 Gy 158 (50) 84 0.09
>60 Gy 156 (50) 89
Fraction dosea
=2 Gy 209 (67) 86 0.38
>2 Gy 105 (33) 88
Field areaa
·35 cm 116 (38) 86 0.80
>35 cm 190 (62) 87
Treatment delaya
·25 days 164 (52) 83 0.10
>25 days 151 (48) 89
Treatment mode
RT only 282 (89) 86 0.34
RT and surgery 34 (11) 90
Treatment era
1982–1985 102 (32) 85 0.18
1986–1989 112 (36) 82
1990–1993 102 (32) 92123
740 Eur Arch Otorhinolaryngol (2009) 266:735–744had undergone a chordectomy and one had irradiation for
mediastinal metastasis. In nine cases, death was caused by
general deterioration due to a second recurrence, one
patient suVered a fatal bleeding from the tumor and two
patients died of post-operative complications (one myocar-
dial infarction and one cerebral vascular accident). The ulti-
mate 5- and 10-year disease-free survival was 97%. In
univariate analysis, age was the only variable of signiWcant
inXuence on disease free survival (P = 0.03). Pre-existent
laryngeal hypertrophic laryngitis was of borderline signiW-
cance (P = 0.20). Ultimately, in multivariate analysis, nei-
ther was found to be of prognostic value (data not shown).
Overall survival
Five- and 10-year overall survival for all 316 patients was
80 and 59%, respectively. Univariate analysis showed only
co-morbidity to be predictive of overall survival (P < 0.01)
with borderline signiWcance for smoking during RT
(P = 0.18), radiation unit (P = 0.18), Weld (P = 0.09) and
additional microsurgery (P = 0.15). In multivariate analy-
sis, only co-morbidity was prognostic for overall survival
with a relative risk of 1.8 (95% CI 1.25–2.69) (data not
shown).
Salvage treatment
Salvage treatment was given in 43 patients. Thirty-eight
patients underwent macro-laryngeal surgery, of whom 35
underwent total laryngectomy, 1 had a hemi-laryngectomy
and 2 had chordectomies. Nine patients with a total laryn-
gectomy also underwent a neck dissection, two of them had
positive lymph nodes. Five patients underwent micro-laryn-
geal surgery of whom four were laser excisions and one
was an excisional biopsy.
Complications of radiotherapy
Three cases of laryngeal edema and two cases of hypothy-
roid necessitating treatment were recorded.
Discussion
This study reports on treatment results and prognostic fac-
tors for local control in a large, population-based series of
consecutive patients treated for T1 glottic carcinoma with
radiotherapy. The average 5-year local control rate of radio-
therapy for T1 glottic cancer in 16 large studies is 84%
(range 78–89%), with an average larynx preservation of
93% [32]. We found a 5-year local control rate of 86% and
a disease-speciWc survival of 97%, which is in accordance
with the literature and supports the consensus that good,
consistent treatment results are achieved with radiotherapy
in T1 glottic carcinoma.
Pre-existent laryngeal hypertrophic laryngitis
Pre-existent laryngeal hypertrophic laryngitis was the only
independent prognostic factor for local control in this
study. It was deWned as pre-existent non-malignant disease
of the larynx, such as leukoplakia or chronic laryngitis
recorded in the charts prior, and separate, to the diagnosis
of invasive carcinoma. In 11 out of 24 patients with pre-
existent laryngeal hypertrophic laryngitis there had been
histological conWrmation of the clinical diagnosis
(Table 3). Pre-existent laryngeal hypertrophic laryngitis
was associated with a relative risk of recurrence of 3.0
(95% conWdence interval 1.2–7.2).
To our knowledge, no other study has yet incorporated
this factor and how exactly pre-existent laryngeal hypertro-
phic laryngitis may inXuence local recurrence is not clear.
One preliminary hypothesis is that the clinical diagnosis
of chronic laryngitis, leukoplakia or hyperkeratosis is
linked to inXammation. InXammatory mediators, such as
Cox-2-derived prostaglandins are potent inXammatory
mediators that promote tumor growth and metastasis
through stimulation of cell proliferation, invasion and angi-
ogenesis, and have been identiWed in laryngeal carcinoma
[24–26]. It is possible that these mediators may also pro-
mote radioresistance. Molecular inhibition of this signaling
system with Cox-2 inhibitors, also in combination with an
EGRF inhibitor, is currently being investigated for potential
combination with radiotherapy in head and neck squamous
cell carcinoma [27, 28]. Another possibility is that pre-exis-
tent laryngeal hypertrophic laryngitis may be indicative of
the large Welds of genetically damaged mucosa containing
precursor lesions, which are often encountered in head and
neck squamous cell carcinoma [29]. Such precursor lesions,
known to be the origin of local recurrence in surgically
treated head and neck cancer [30] may also be less sensitive
to radiotherapy and therefore go on to develop recurrences
which are actually second Weld tumors. Further investiga-
tions are warranted to conWrm if, and by what mechanism,
chronic, pre-existent laryngeal hypertrophic laryngitis
Table 6 Multivariate analysis (Cox regression)
N = 313, three cases dropped due to missing values
P value RR 95% CI 
interval
Pre-existent hypertrophic laryngitis 0.02 3.0 1.2–7.2
Tumor size 0.07
Total dose 0.90
Treatment era 0.64
Treatment delay 0.20
Overall treatment time 0.48123
Eur Arch Otorhinolaryngol (2009) 266:735–744 741contributes to low but steady rate of local recurrence in T1
glottic carcinoma treated with radiotherapy.
Other factors in local control
No other factor was found to be predictive for local control
in this study. As stated in the introduction, the literature on
early glottic carcinoma is extensive and contradictory. For
instance, several publications Wnd a signiWcant inXuence of
tumor size/extension on local control, whereas others do
not (Table 1). Also, although the majority of studies,
including our own population-based study, Wnd no evidence
of inXuence of anterior commissure involvement on local
control, three studies do Wnd an inXuence, including a large
Italian study of 831 patients [6]. It is interesting, however,
that the only prospective randomized trial to date does not
Wnd a signiWcant inXuence of anterior commissure involve-
ment on local control [7]. Accurate data on the impact of
these two factors (size/extension and anterior commissure
involvement) on treatment outcome is particularly relevant
today with regard to deWning the indications for laser sur-
gery. Other prognostic factors identiWed with a varying
degree of consistency are continued smoking during and
after radiotherapy [5], low hemoglobin levels [15], poorly
diVerentiated tumors (ref), large Welds (>36 cm2) [12, 19]
and the time-dose parameters that will be discussed sepa-
rately below. As of yet, no systematic review or meta-anal-
ysis of these data has been published. Due to Lack of
reliable comparative outcome analysis, identifying depend-
able prognostic factors remains a problem. Inconsistencies
in the deWnition of prognostic factors (such as tumor size/
extension) may be one explanation for the conXicting
results, although the discrepancy between the relatively
steady failure rates and the Xuctuating Wndings on prognos-
tic factors suggests that there may be important prognostic
factors that are as of yet insuYciently identiWed.
However, a few cautious conclusions can be drawn from
current data. Firstly, there is insuYcient ground to distin-
guish between T1a versus T1b stage tumors as far as radio-
therapy is concerned. The overwhelming majority of
studies do not Wnd this sub-staging a prognostic factor. Sec-
ondly, several studies have shown that the time-dose
parameters have a signiWcant impact on treatment outcome.
At the same time, several authors have also warned for the
complex relationship between total dose, fraction size and
overall treatment time [18, 20]. The total dose given often
varies within a study, thus compensating and possibly
masking the eVect of smaller fraction sizes or longer treat-
ment times. Although most studies enter factors individu-
ally into multivariate analysis, comparing whole
fractionation schedules is therefore preferable to analyzing
individual factors. Van der Voet [20] showed that locore-
gional control increased when the total dose was given in
higher fractions and thus shorter time. These results were
conWrmed in the prospective, randomized trial of Yamazaki
[7]. Both authors argued that overall treatment time was the
determinant factor in the time-dose relationship and both
recommend the use of fraction sizes higher than that of the
conventional 2 Gy (van der Voet 2.4 Gy and Yamazaki
2.25 Gy) to reduce overall treatment time. Dinshaw [12],
however, found equal outcomes for his diVerent fraction-
ation schedules. In our study, 157 patients (50%) were
treated with a standard regimen of 30 £ 2 Gy [12]. The
other half was treated with varying schedules. In all cases
but one these schedules resulted in a higher total dose either
through a higher dose per fraction or through a higher num-
ber of fractions. As there were too many diVerent schedules
for analysis in this second group, we chose to combine
them and to compare them to the standard schedule of
30 £ 2 Gy. The alternative schedules showed a borderline
impact in univariate analysis (Table 3). This signiWcance
was, however, lost in multivariate analysis.
As stated, several authors have argued that of the indi-
vidual time-dose parameters overall treatment time is the
most important, Wnding decreased local control rates with
prolong overall treatment time [2, 4, 7, 20]. Rudoltz [4]
showed a decrease in local control with increasing treat-
ment time (<43 days: 100%; 43–46 days: 91%, 47–50 days:
74%, 51–54 days: 65% and >55 days 50%). Gowda and
Mendenhall [31] also showed that, shorter treatment time/
larger fraction doses resulted in higher rates of local control
and larynx preservation without a signiWcant increase in
acute morbidity. Skladowski [18] showed that prolonging
treatment time due to interruption had a negative inXuence
on local control with each day of extension producing a
1.3% loss in local control in his model and Groome [13]
found the same for more than four treatment brakes. The
above-mentioned studies recommend limiting treatment
duration by avoiding interruption due to holidays, as well
as using shorter fractionation schedules.
Interestingly, as seen from Table 1 most studies actually
fail to show a signiWcant impact on local control of the time-
dose related factors. Most likely, this is because the complex
relationship between the factors may mask their signiWcance
in simple univariate/multivariate analysis as discussed earlier.
It has also been suggested that any diVerences may be
obscured by the fact that schedule variation is limited and the
doses used in most series are already on the plateau of the sig-
moid tumor-curve [18]. Despite this discrepancy, the concept
of increased local control with shorter treatment time has
become commonly accepted, as has that of the negative inXu-
ence of treatment brakes. In the year 2000, the positive impact
of shorter treatment times on local control led to the introduc-
tion of an accelerated schedule of 25 £ 2.4 Gy as an alterna-
tive to the standard schedule of 30 £ 2 Gy in the Dutch
national guideline for the treatment of laryngeal cancer (ref).123
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In multivariate analysis, we found no factor prognostic for
disease-speciWc survival and only co-morbidity was prognos-
tic for overall survival. The fact that age was not prognostic
for overall survival, although the expected trend was seen for
older age groups, was probably due to the relatively poor sur-
vival of the youngest age group (<50 years). This is also indi-
cated by the fact that age, on the basis of the youngest age
group, was a signiWcant factor for decreased disease-speciWc
survival in univariate analysis (data not shown).
As for the relevance of the current Wndings, the question
arises if patients with pre-existent laryngeal hypertrophic
laryngitis should be routinely treated with the alternative to
radiotherapy: laser surgery. It has long been known that
both radiotherapy and laser surgery are viable treatment
options for T1 glottic carcinoma. For laser surgery,
reported local control has typically been slightly higher
than for radiotherapy (see above), although many studies
consist only of selected and often superWcial mid-cord T1a
lesions treatable with a subepithelial or subligamental
resection (type I/II ELS classiWcation [32]. The average
5-year rate of local control was 92% (88–94%) with an
average larynx preservation of 98% in ten such studies on
selected T1a lesions [33]. Voice quality after laser resection
of superWcial, mid-cord T1a lesions is found to be good and
often comparable to normal [30–33]. Although no random-
ized trial has yet been performed, from these retrospective
data local control rates in selected T1a can be considered at
least comparable to radiotherapy. Providing similar voice
quality to radiotherapy [33–39] and the additional beneWts
of shorter treatment time, lower costs and the possibility of
repeated procedures, laser surgery is already the preferred
treatment for superWcial T1a midcord lesions according to
Dutch National Guidelines and at our institution.
In six studies on unselected T1 lesions (T1a and T1b)
treated with laser surgery, the average 5-year local control
was 88% (81–93%) and larynx preservation was 98% [32].
Seeing these results, the question, whether patients with T1
glottic carcinoma with pre-existent laryngeal hypertrophic
laryngitis should be routinely treated with laser surgery, or
whether all patients with T1 glottic carcinoma should be
routinely treated with laser surgery rises. Theoretically,
laser surgery as a primary treatment option should lead to
higher rates of organ preservation as it allows for multiple
resections with radiotherapy, kept as a reserve for surgical
failures. This is illustrated by the diVerence in average
larynx preservation between radiotherapy (93%) and laser
surgery (98%) discussed earlier.
The main obstacle in extending the indications for laser
surgery to larger T1 lesions is the uncertainty over func-
tional outcome after more extensive resections. Although
most surgeons would agree that larger and deeper lesions,
and therefore more extensive resections, will have signiW-
cantly worse functional outcome, there is still not much
multidimensional voice data for how worse this will be.
The conclusion of a recent Cochrane analysis was that
“there is currently insuYcient evidence to guide manage-
ment decisions on the most eVective treatment”. Further-
more, investigations into prognostic factors for failure in
laser surgery are currently limited to a few small studies
[39–43]. For example, neither the inXuence of T-stage nor
the anterior commissure invasion on local control is clear.
The lack of reliable comparative outcome analysis for the
two treatment modalities is likely to cause a lack of coher-
ent practice guidelines for some time to come.
What then, in this general debate, can be said about patients
with pre-existent laryngeal hypertrophic laryngitis? First of all,
issues over functionality would seem equally relevant to
patients with pre-existent laryngeal hypertrophic laryngitis.
Whether these patients and their treating physicians would be
willing to oVer voice function for a higher chance of eventu-
ally preserving their larynx is unknown. Furthermore, one of
the contraindications for laser surgery is the inability to delin-
eate the circumference of the tumor. In patients with pre-exis-
tent laryngeal hypertrophic laryngitis, it may be particularly
diYcult to achieve a macroscopically radical resection making
them less suitable for laser surgery. Therefore, theoretically
these patients may end up having higher rates of residual dis-
ease than average for laser surgery. However, by choosing
laser surgery in these patients the options of additional treat-
ment via re-resection and/or radiotherapy have been kept
open. Whether this advantage outweighs the higher chance of
residual disease remains to be seen in further research.
In summary, the literature on prognostic factors in T1
glottic carcinoma is contradictory. Our population-based
study has shown that patients with pre-existent laryngeal
disease are at a greater risk of local recurrence. As this is
the Wrst study to identify this prognostic factor, further
investigation of this and other variables in prospective, ran-
domized trials are essential. Furthermore, laser surgery
should be considered when treating patients with pre-existent
laryngeal hypertrophic laryngitis and delineated disease.
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